COLORECTAL NEOPLASMS

This trial tests a new drug, UCB4594, designed to help the immune system attack cancer cells by targeting a protein called HLA-G found on many tumors. It is for people with advanced solid cancers that have not responded to standard treatments. The study aims to find the safest do…

This study tests whether a new drug called amivantamab, combined with standard chemotherapy (FOLFIRI), helps people with a certain type of advanced colorectal cancer live longer without their disease getting worse. It is for patients whose cancer has returned or spread and who ha…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with certain cancers and children aged 12…

This study tests a new drug called LY4337713, which delivers radiation directly to cancer cells that have a specific protein (FAP). It is for adults with advanced or spread-out cancers like pancreatic, breast, ovarian, colorectal, esophageal, stomach, or bile duct cancer. The mai…

This study compares two drug combinations as first treatment for people with a specific type of advanced colorectal cancer that cannot be removed by surgery or has spread. About 1000 adults will receive either amivantamab plus chemotherapy or cetuximab plus chemotherapy. The goal…

This study tests a new drug called LY4257496 that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, prostate, colorectal, or endometrial cancer that has spread. The goal is to see if the drug is safe and can shrink …

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard liver-directed chemotherapy can help people with certain cancers that have spread to the liver. About 70 adults with colorectal cancer, bile duct cancer, or adrenal cancer that is mainly in the liver w…

This study compares the immunotherapy drug pembrolizumab with standard chemotherapy in 100 Chinese patients whose advanced colorectal cancer has specific genetic markers (MSI-H or dMMR). The goal is to see if pembrolizumab can better delay cancer growth or improve survival. Parti…

This early-phase study tests a new drug called DM002 in 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by testing low to higher doses in small groups; second, giving t…

This study compares a yearly stool test (FIT) to a colonoscopy every few years for people who have had polyps removed. The goal is to see if the simpler test works just as well to catch new cancers or high-risk polyps. 4,000 adults who had an advanced polyp removed will be follow…

This study tests whether adding tucatinib and trastuzumab to standard chemotherapy helps people with HER2-positive colorectal cancer that has spread or can't be removed by surgery. About 400 participants will be randomly assigned to receive either the new drug combo or standard t…

This study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib), with or without immunotherapy, can control advanced colorectal cancer without chemotherapy. About 70 adults with a specific genetic type (RAS/BRAF wild-type) will receive these drugs as th…

This early-stage study tests a new drug called AZD9592, alone or with other cancer treatments, in people with advanced solid tumors (lung, head & neck, or colorectal cancer that has spread). The main goals are to check safety, find the right dose, and see if it shrinks tumors. Ab…

This study tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with other rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various tumor types will receive the drug com…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 adults with lung, colorectal, endometrial, ovarian, pancreatic, or bile duct c…

This early-phase study tests an experimental drug called JNJ-89402638 in people with advanced colorectal or stomach cancer that has spread and not responded to prior treatments. The study will also test the drug combined with bevacizumab (with or without chemotherapy) for colorec…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…

This trial tests a drug called atezolizumab, already approved for some cancers, in people with rare cancers that have high numbers of genetic mutations or specific DNA repair problems. About 30 adults and children with these rare tumor types will receive the drug. The main goal i…

This study tests a new experimental drug, PF-07934040, for people with advanced solid tumors that have a KRAS gene mutation. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV. The goal is to find the safest dose and see if the d…

This study tests a new medicine, PF-08634404, combined with chemotherapy against the standard treatment (bevacizumab plus chemotherapy) in people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly assi…

This study looks at whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine) based on a person's DPYD gene test can reduce severe side effects. About 100 adults with certain cancers (like colorectal, breast, or head/neck) will take part. The goal is to see if perso…

This early-stage study is testing a new drug called JNJ-95437446 in about 380 adults with advanced solid tumors, including colorectal, lung, and head and neck cancers that have spread or cannot be removed. The main goals are to find safe doses and check for side effects. Research…

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…

This study tests an experimental drug called PF-08046050 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to stick to cancer cells and kill them. The main goal is to check safety and find the right dose. About 914 adults wi…

This study tests a new microwave-based device that helps doctors find polyps during colonoscopy. About 50 people who already have a polyp in their rectum will take part. The device is used alongside standard colonoscopy to see if it can detect more polyps without causing harm.

This study is developing a blood test to detect colorectal cancer in people under 50, a group where cases are rising. The test looks at tiny particles called exosomes and uses machine learning to find cancer signals. Researchers will enroll 400 participants—half with early-onset …

This study tests whether using an artificial intelligence (AI) system during screening colonoscopy can reduce the chance of developing advanced polyps or colorectal cancer three years later. About 592 adults who need a screening colonoscopy will be randomly assigned to have the p…

This study tests a 12-week program that includes workshops, online support, daily check-ins, and peer buddies to help people at high risk for colorectal cancer improve their diet, exercise, and other habits. Researchers will compare participants who get the program to those who r…

This study tests whether adding dexmedetomidine to standard anesthesia (desflurane) helps people undergoing laparoscopic colon surgery. Researchers want to see if the combination reduces the amount of anesthesia needed, keeps heart rate and blood pressure more stable during surge…

This study tests whether a virtual hub offering personalized education, exercise, nutrition, and peer support before and after surgery can reduce complications within 30 days. About 564 adults in Australia having colorectal cancer surgery will be randomly assigned to the hub plus…

This study looks at how chemotherapy and radiation affect the reproductive and sexual health of young adults with early-onset colorectal cancer. Researchers will track hormone levels and ask participants about their sexual health and ability to have children. The goal is to bette…

This study is a registry for adults having surgery for colorectal cancer. It collects medical information and stores tumor tissue and blood samples to analyze genetic changes and biomarkers. The goal is to better understand the disease and track long-term outcomes like survival a…

This study aims to confirm that a blood test detecting tumor DNA after colorectal cancer surgery can better predict the risk of cancer returning than current methods. Researchers will follow 1,600 patients who had surgery for stage I-III colorectal cancer to see if the test resul…

This study looks at the best time to start eating after a colon procedure called endoscopic submucosal dissection (ESD) for removing large polyps or early cancers. About 204 adults will be randomly assigned to start eating within 24 hours or wait longer. The goal is to see which …

This study takes tumor samples from people with breast, colorectal, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to match patients with effective treatments and…

This study looks at two ways to check for colon cancer in adults aged 65 to 82 who have had colon polyps before. One group will get a yearly stool test (FIT), and the other will have a colonoscopy. Researchers want to see which method finds advanced growths better over time. Abou…

This study collects tumor and nearby normal tissue samples from people already scheduled for surgery or biopsy at the NIH Clinical Center. Up to 1,800 adults and children (age 2+) with solid tumors can join. The samples are used to identify new molecular targets for future cancer…